Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents

American Journal of Obstetrics and Gynecology

Volumn 208, Issue 1, 2013, Pages 64.e1-64.e7

  Tunks, Robert D ^a   Clowse, Megan E B ^a   Miller, Stephen G ^a   Brancazio, Leo R ^a   Barker, Piers C A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autoantibodies; congenital heart block; fetal echocardiography; prevention

Indexed keywords

AUTOANTIBODY; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; CLINICAL ARTICLE; CONGENITAL HEART BLOCK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART CONDUCTION; HUMAN; MEDICAL RECORD REVIEW; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW;

EID: 84871608207     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2012.09.020     Document Type: Article

References (25)

1. A. Brucato, M. Frassi, F. Franceschini Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women Arthritis Rheum 44 2001 1832 1835
2. S. Vesel, U. Mazic, T. Blejec, T. Podnar First-degree heart block in the fetus of an anti-SSA/Ro-positive mother: reversal after a short course of dexamethasone treatment Arthritis Rheum 50 2004 2223 2226
3. D. Spence, L. Hornberger, R. Hamilton, E.D. Silverman Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies J Rheumatol 33 2006 167 170
4. J.P. Buyon, E. Ben-Chetrit, S. Karp Acquired congenital heart block: pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus J Clin Invest 84 1989 627 634
5. E. Jaeggi, C. Laskin, R. Hamilton, J. Kingdom, E. Silverman The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants J Am Coll Cardiol 55 2010 2778 2784
6. S. Salomonsson, T. Dorner, E. Theander, K. Bremme, P. Larsson, M. Wahren-Herlenius A serologic marker for fetal risk of congenital heart block Arthritis Rheum 46 2002 1233 1241
7. S.E. Sonesson, S. Salomonsson, L.A. Jacobsson, K. Bremme, M. Wahren-Herlenius Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies Arthritis Rheum 50 2004 1253 1261
8. D.M. Friedman, M.Y. Kim, J.A. Copel Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR interval and dexamethasone evaluation (PRIDE) prospective study Circulation 117 2008 485 493
9. E.T. Jaeggi, E.D. Silverman, C. Laskin, J. Kingdom, F. Golding, R. Weber Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block: a prospective observational study on the effects of maternal antibodies on 165 fetuses J Am Coll Cardiol 57 2011 1487 1492
10. J. Glickstein, J. Buyon, M. Kim, D. Friedman The fetal Doppler mechanical PR interval: a validation study Fetal Diagn Ther 19 2004 31 34
11. N. Costedoat-Chalumeau, Z. Amoura, D. Le Thi Hong Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block Ann Rheum Dis 62 2003 1010 1012
12. P.M. Izmirly, M.Y. Kim, C. Llanos Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine Ann Rheum Dis 69 2010 1827 1830
13. P.M. Izmirly, N. Costedoat-Chalumeau, C. Pisoni Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus Circulation 126 2012 76 82
14. D.M. Friedman, C. Llanos, P.M. Izmirly Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial Arthritis Rheum 62 2010 1138 1146
15. J.P. Buyon, R. Hiebert, J. Copel Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry J Am Coll Cardiol 31 1998 1658 1666
16. K. Shinohara, S. Miyagawa, T. Fujita, T. Aono, K. Kidoguchi Neonatal lupus erythematosus: results of maternal corticosteroid therapy Obstet Gynecol 93 1999 952 957
17. J. Waltuck, J.P. Buyon Autoantibody-associated congenital heart block: outcome in mothers and children Ann Intern Med 120 1994 544 551
18. E.T. Jaeggi, E.D. Silverman, S.J. Yoo, J. Kingdom Is immune-mediated complete fetal atrioventricular block reversible by transplacental dexamethasone therapy? Ultrasound Obstet Gynecol 23 2004 602 605
19. D.M. Friedman, A. Rupel, J.P. Buyon Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus Curr Rheumatol Rep 9 2007 101 108
20. J.M. Breur, G.H. Visser, A.A. Kruize, P. Stoutenbeek, E.J. Meijboom Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature Ultrasound Obstet Gynecol 24 2004 467 472
21. S.T. Liu, C.R. Wang, G.D. Yin Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus Asian Pac J Allergy Immunol 19 2001 29 35
22. N. Costedoat-Chalumeau, Z. Amoura, G. Aymard Evidence of transplacental passage of hydroxychloroquine in humans Arthritis Rheum 46 2002 1123 1124
23. M.E. Clowse, L. Magder, F. Witter, M. Petri Hydroxychloroquine in lupus pregnancy Arthritis Rheum 54 2006 3640 3647
24. D.E. Moller, R.E. Ratner, D.G. Borenstein, S.I. Taylor Autoantibodies to the insulin receptor as a cause of autoimmune hypoglycemia in systemic lupus erythematosus Am J Med 84 1988 334 338
25. J.M. Li, A.C. Horsfall, R.N. Maini Anti-La (SS-B) but not anti-Ro52 (SS-A) antibodies cross-react with laminin-a role in the pathogenesis of congenital heart block? Clin Exp Immunol 99 1995 316 324